TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30898098

Group type: EXPERIMENTAL
Intervention: Second look diagnostic laparoscopy (DLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third look DLS after negative second look DLS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine follow-up including 18 months abdominal CT
Number of subjects: 0
Study: 28171855

Group type: EXPERIMENTAL
Intervention: High-dose group (n = 98)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard-dose group (n = 65)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 163
Study: 26048730

Group type: EXPERIMENTAL
Intervention: TXA 500 mg intra-articular injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline intra-articular injection (control)
Number of subjects: 60
Study: 23740284

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 mcg/kg/min fixed-dose)
Number of subjects: 20
Study: 21716593

Group type: EXPERIMENTAL
Intervention: D-003 (10 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 19347740

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 82
Study: 16443054

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 653

Group type: COMPARATOR
Intervention: Adapalene gel 0.1%
Number of subjects: 653

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 653
Study: 12093655

Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering treatment (mainly beta-blockers)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering treatment (n = 33)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Treated persons with open-angle glaucoma
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Treated persons without open-angle glaucoma
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Newly detected (untreated) glaucoma at baseline
Number of subjects: 2609
Study: 10362413

Group type: EXPERIMENTAL
Intervention: 546C88 at 1 mg/kg/hr
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 546C88 at 2.5 mg/kg/hr
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 546C88 at 5 mg/kg/hr
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 546C88 at 10 mg/kg/hr
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 546C88 at 20 mg/kg/hr
Number of subjects: 32
Study: 8750372

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg with losartan 50 mg
Number of subjects: 12
Study: 2053226

Group type: EXPERIMENTAL
Intervention: 90 mg of norfenefrine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6445254

Group type: EXPERIMENTAL
Intervention: Hormonal methods (several androgen/gestagen combinations and cyproterone acetate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other male methods known or experienced by users
Number of subjects: 0
Study: 6365516

Group type: EXPERIMENTAL
Intervention: Milk-based formula supplement providing 800 kcal and 40 g protein daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo providing less than 40 kcal per diem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk-based formula supplement
Number of subjects: 0
Study: 30711327

Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Bubble-blowing
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Jet lidokaine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with lavender essence
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control
Number of subjects: 195
Study: 30211823

Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab 300 mg once weekly (qw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27767433

Group type: EXPERIMENTAL
Intervention: Acupuncture (n=15); treatment for 30 days, once weekly for 5 sessions.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Carprofen (4.4 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (lactose capsules, 1 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Number of subjects: 47
Study: 24072404

Group type: EXPERIMENTAL
Intervention: Non-revision surgery patients (N=137)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Implant removal patients (N=38)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Revision arthroplasty patients (N=67)
Number of subjects: 248
Study: 22172243

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Baseline GSM
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Common CIMT
Number of subjects: 984
Study: 20930165

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (multicomponent treatment including aspirin)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 433
Study: 18586898

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 40
Study: 16103773

Group type: EXPERIMENTAL
Intervention: HIVNET 012 (nevirapine)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Thai-CDC (zidovudine)
Number of subjects: 76
Study: 14689885

Group type: EXPERIMENTAL
Intervention: Catheter depth of 2 cm and infused semen volume of 0.3 ml
Number of subjects: 330

Group type: COMPARATOR
Intervention: Catheter depth of 1 cm and infused semen volume of 0.5 ml
Number of subjects: 330

Group type: COMPARATOR
Intervention: Catheter depth of 1 cm and infused semen volume of 0.3 ml
Number of subjects: 330

Group type: COMPARATOR
Intervention: Catheter depth of 2 cm and infused semen volume of 0.5 ml
Number of subjects: 330

Group type: COMPARATOR
Intervention: Catheter depth of 3 cm and infused semen volume of 0.5 ml
Number of subjects: 330

Group type: COMPARATOR
Intervention: Catheter depth of 3 cm and infused semen volume of 0.3 ml
Number of subjects: 330
Study: 10494584

Group type: COMPARATOR
Intervention: Intravenous nicotine (0, 3.5, 7, 14, and 28 micrograms/kg)
Number of subjects: 14
Study: 8671479

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sonographically controlled selective tubal catheterization (STC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hysterosalpingo-contrast sonography followed by STC
Number of subjects: 26

Group type: COMPARATOR
Intervention: STC followed by hysterosalpingo-contrast sonography
Number of subjects: 26
Study: 1816570

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 and 0.5 mg/70 kg of body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6752963

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam suppositories
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam suppositories
Number of subjects: 24
Study: 31917849

Group type: EXPERIMENTAL
Intervention: Fast scanning mode (energy level of 110 nJ, spot distance of 4.5 mm)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard scanning mode (energy level of 105 nJ, spot distance of 3 mm)
Number of subjects: 39
Study: 30783735

Group type: EXPERIMENTAL
Intervention: EH15.5%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EH13.5%
Number of subjects: 10

Group type: COMPARATOR
Intervention: EN
Number of subjects: 10
Study: 29609240

Group type: EXPERIMENTAL
Intervention: Elderly population surveyed
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Elderly females
Number of subjects: 5376

Group type: COMPARATOR
Intervention: Elderly males
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 5376

Group type: COMPARATOR
Intervention: Rural residents
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Southern area residents
Number of subjects: 5376

Group type: COMPARATOR
Intervention: Northern area residents
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Age group 60 years
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Age group 65 years
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Age group 70 years
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Age group 75 years
Number of subjects: 5376

Group type: EXPERIMENTAL
Intervention: Age group 80 years
Number of subjects: 5376
Study: 27607363

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24493848

Group type: EXPERIMENTAL
Intervention: Contextual fear conditioning and extinction manipulation
Number of subjects: 0
Study: 22704391

Group type: EXPERIMENTAL
Intervention: eCG (50 IU/kg im) followed by hCG (500 IU im)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (1 mL saline solution im)
Number of subjects: 25
Study: 20199535

Group type: EXPERIMENTAL
Intervention: Directional stylet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hockey-stick stylet
Number of subjects: 10

Group type: COMPARATOR
Intervention: No stylet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Styletted tracheal tube
Number of subjects: 10
Study: 17379432

Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg three times daily (with possible escalation to 45 mg)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Cevimeline 30-45 mg three times daily
Number of subjects: 570
Study: 16274375

Group type: EXPERIMENTAL
Intervention: Combined report intervention (6 physicians and 198 patients received reports and education)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Patient report intervention (245 patients received reports and education without physician reports)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 665
Study: 12209482

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study: 10206288

Group type: EXPERIMENTAL
Intervention: Fractional polynomials for prognostic modeling
Number of subjects: 686

Group type: COMPARATOR
Intervention: Traditional approaches using categorized variables or straight line relationships
Number of subjects: 686
Study: 7754988

Group type: EXPERIMENTAL
Intervention: Cretan Mediterranean diet
Number of subjects: 605

Group type: COMPARATOR
Intervention: Usual prescribed diet
Number of subjects: 605
Study: 2268862

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 7005653

Group type: EXPERIMENTAL
Intervention: Dentrifrice containing 0.25% fluorine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Similar toothpaste containing fluorine
Number of subjects: 42
Study: 28976249

Group type: EXPERIMENTAL
Intervention: Gait training with auditory feedback caused by active weight bearing on the paralyzed side (experimental group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: General gait intervention over the ground (control group)
Number of subjects: 24
Study: 27256080

Group type: EXPERIMENTAL
Intervention: Wii group (WG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study: 25992746

Group type: EXPERIMENTAL
Intervention: Fixed course of antibiotics for 4±1 calendar days
Number of subjects: 518

Group type: COMPARATOR
Intervention: Antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, maximum of 10 days
Number of subjects: 518
Study: 22967857

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group (non-overvaluation)
Number of subjects: 90
Study: 21593290

Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss (LWL) intervention through a diabetes education program (DEP) delivered by community health workers (CHWs)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Enhanced usual-care condition
Number of subjects: 301
Study: 19696287

Group type: EXPERIMENTAL
Intervention: Contrast material of 300 mg I/mL (Protocol A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Contrast material of 370 mg I/mL (Protocol B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Contrast material of 370 mg I/mL plus saline flush (Protocol C)
Number of subjects: 36
Study: 16809571

Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) infusion, doses ranging from 0.34 to 2.05 g/kg, administered over 2 hours within 16 hours of stroke onset
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard-of-care intravenous tissue plasminogen activator (tPA)
Number of subjects: 82
Study: 12777860

Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (daclizumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10966537

Group type: EXPERIMENTAL
Intervention: Clinical data from the Cardiac Care Network of Ontario
Number of subjects: 9

Group type: COMPARATOR
Intervention: Administrative data from the Canadian Institute for Health Information
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both data sources
Number of subjects: 9
Study: 8603263

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia at 40 degrees C
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia at 42 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 6
Study: 1540491

Group type: EXPERIMENTAL
Intervention: (+)-R-nitrendipine 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (-)-S-nitrendipine 20 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: R,S-nitrendipine (pseudoracemic mixture of 10 mg (+)-R and 10 mg (-)-S)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: R-nitrendipine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S-nitrendipine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Major pyridine metabolite M1
Number of subjects: 6
Study: 4001300

Group type: EXPERIMENTAL
Intervention: Professionally provided program of social support counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31982540

Group type: EXPERIMENTAL
Intervention: Regular paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol as-needed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29804552

Group type: EXPERIMENTAL
Intervention: Modified report intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard report control
Number of subjects: 110
Study: 26435472

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 0
Study: 26543177

Group type: EXPERIMENTAL
Intervention: v‐gel supraglottic airway device (SGAD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: endotracheal tube (ETT)
Number of subjects: 33
Study: 24075125

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22057726

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 7185
Study: 19147639

Group type: EXPERIMENTAL
Intervention: Topical chloramphenicol (n=488)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Paraffin ointment (n=484; placebo)
Number of subjects: 972
Study: 16785075

Group type: EXPERIMENTAL
Intervention: Citracal tablet providing 315 mg of elemental calcium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OsCal tablet providing 500 mg of elemental calcium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: People's Choice tablet providing 600 mg of elemental calcium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablet
Number of subjects: 36
Study: 15479445

Group type: EXPERIMENTAL
Intervention: Divergence, curl, mean and Gaussian curvatures of the flow field combined with skin line direction
Number of subjects: 0
Study: 11034038

Group type: EXPERIMENTAL
Intervention: Oral phytonadione 2.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9063425

Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (ADC) - brompheniramine maleate-phenylpropanolamine hydrochloride
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (ADC)
Number of subjects: 59
Study: 7981078

Group type: EXPERIMENTAL
Intervention: MPH-P (melphalan and prednisone)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Peptichemio, vincristine, and prednisone)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: MPH-P
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 281

Group type: COMPARATOR
Intervention: MPH-P and combination chemotherapy
Number of subjects: 281
Study: 2662452

Group type: EXPERIMENTAL
Intervention: Cefotetan alone (n = 315)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Cefotetan and metronidazole (n = 300)
Number of subjects: 615
Study: 4527847

Group type: EXPERIMENTAL
Intervention: CAPA (cyclophosphamide, cytosine arabinoside, prednisolone, and L asparaginase)
Number of subjects: 71

Group type: COMPARATOR
Intervention: CAP (cyclophosphamide, cytosine arabinoside, and prednisolone)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CAPA
Number of subjects: 71
Study: 30597537

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study: 28355113

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (62 Gy in 20 fractions in 5 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional radiotherapy (80 Gy in 40 fractions in 8 weeks)
Number of subjects: 168
Study: 26135582

Group type: EXPERIMENTAL
Intervention: Non-dispensing pharmacist as an integral member of a primary care team
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Pharmacist in a community pharmacy with predefined training in performing medication reviews
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Pharmacist in a community pharmacy (care as usual)
Number of subjects: 10000
Study: 24691455

Group type: EXPERIMENTAL
Intervention: Complex critical care ventilator (Group B and C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Complex critical care ventilator (Group C)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional mini-ventilator (Group A)
Number of subjects: 51
Study: 22759218

Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 60
Study: 20097330

Group type: EXPERIMENTAL
Intervention: Vague feedback about performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Precise feedback about performance
Number of subjects: 0
Study: 18192779

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in primary HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy of a limited duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPARTAC trial
Number of subjects: 0
Study: 15910348

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with epinephrine 1:200,000 and clonidine 2 microg.kg‐1 (group-C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.125% bupivacaine with epinephrine 1:200,000 (group-NC)
Number of subjects: 30
Study: 12911201

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg x kg(‐1)) and propofol (1.8 mg x kg(‐1))
Number of subjects: 263

Group type: COMPARATOR
Intervention: N2O/sevoflurane (4% sevoflurane in N2O at 41 x min(‐1) and oxygen at 21 min(‐1)) and propofol (1.8 mg x kg(‐1))
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 263

Group type: COMPARATOR
Intervention: N2O/sevoflurane
Number of subjects: 263
Study: 10555905

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9315416

Group type: EXPERIMENTAL
Intervention: Deep injection of local anesthetics (n = 31), paracervical block involving four injections approximately 3 cm deep
Number of subjects: 66

Group type: COMPARATOR
Intervention: Regular injection of local anesthetics (n = 35), paracervical block involving four injections approximately 1.5 cm deep
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Deep injection of local anesthetics (n = 31)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Regular injection of local anesthetics (n = 35)
Number of subjects: 66
Study: 8436146

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg t.i.d. as additive treatment to morphine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg t.i.d.
Number of subjects: 15
Study: 3014855

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (500 mg elemental calcium)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (500 mg elemental calcium)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29162331

Group type: EXPERIMENTAL
Intervention: High load at 100% body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low load at 20% body weight
Number of subjects: 20
Study: 27574730

Group type: EXPERIMENTAL
Intervention: Conditioning procedure on pain tolerance with belief in analgesic treatment (Experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No previous conditioning procedure (Experiment 2)
Number of subjects: 0
Study: 23039403

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once a day
Number of subjects: 205
Study: 22726241

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4, 0.6 and/or 0.8 U/kg once daily for two 6-day periods
Number of subjects: 49